Research Study
View Full Study →
Chronic low-dose REV-ERBs agonist SR9009 mitigates constant light-induced weight gain and insulin resistance via adipogenesis modulation.
Citation
Yang M., Lin H., Chen Y., Hu M., Chen I. et al. (2025). Chronic low-dose REV-ERBs agonist SR9009 mitigates constant light-induced weight gain and insulin resistance via adipogenesis modulation.. Biomed J. DOI: 10.1016/j.bj.2025.100830
Abstract
Abstract not available. See citation for source.
Disclaimer: This research summary is for educational purposes only. Always consult with a healthcare professional before making decisions based on scientific research.